Idiopathic Intracranial Hypertension
High pressure in the brain without a tumor, causing severe daily headaches and risking blindness due to pressure on the optic nerves.
Emergency Management: Fulminant IIH with precipitous visual decline over days requires immediate hospitalization, high-dose IV steroids (controversial but used as a bridge), serial lumbar punctures, and urgent surgical intervention (shunting or ONSF).
Idiopathic Intracranial Hypertension (IIH) is a neurological disorder characterized by elevated intracranial pressure (ICP) in the absence of an intracranial space-occupying lesion, hydrocephalus, or abnormal cerebrospinal fluid (CSF) composition.
Detailed Overview
IIH primarily affects obese women of childbearing age. The exact mechanism is unknown but involves impaired CSF absorption, increased venous sinus pressure, or endocrine factors. Elevated ICP transmits along the optic nerve sheath, leading to papilledema (optic disc swelling), which is the most critical clinical feature. While the condition was historically termed 'benign', it carries a severe risk of permanent visual field loss and irreversible blindness if not treated promptly to lower ICP.
Epidemiology & Demographics
Incidence is 1-2 per 100,000 in the general population, but rises drastically to 20 per 100,000 in obese women aged 20-44 years.
Etiological Mechanism
Idiopathic by definition, but strongly associated with obesity, weight gain, and specific medications.
Primary Causes
["Idiopathic (primary)", "Secondary (Pseudotumor cerebri syndrome) induced by medications: Tetracyclines, Vitamin A derivatives (Isotretinoin), Lithium, prolonged steroid withdrawal."]
The precise pathophysiology is debated. Hypotheses include: 1) Increased cerebral venous pressure (e.g., transverse sinus stenosis) impeding CSF drainage through arachnoid granulations. 2) Dysregulation of CSF production by the choroid plexus. 3) Obesity-related hormonal changes (e.g., increased intra-abdominal pressure increasing venous pressure, or adipokines driving inflammation). The elevated ICP causes mechanical compression and ischemia of optic nerve axons at the lamina cribrosa, resulting in axoplasmic flow stasis and papilledema.
Diagnostic Criteria & Guidelines
Modified Dandy Criteria: 1) Signs and symptoms of increased ICP. 2) Absence of localizing neurologic signs (except CN VI palsy). 3) Normal neuroimaging (MRI/MRV must rule out masses, hydrocephalus, and venous sinus thrombosis). 4) Normal CSF composition. 5) Elevated CSF opening pressure (>250 mmH2O in adults).
Carbonic anhydrase inhibitors to decrease CSF production: Acetazolamide starting at 500 mg BID, titrated up to 2-4 g/day as tolerated (monitor for paresthesias, hypokalemia). Weight loss is mandatory (target 5-10% reduction).
Second-Line & Adjunctive Therapy
Topiramate 25-50 mg BID (has the dual benefit of headache prophylaxis and promoting weight loss, as well as mild carbonic anhydrase inhibition). Furosemide can be used as an adjunct.
Surgical & Procedural Management
For rapidly progressive visual loss or failed medical therapy: Optic nerve sheath fenestration (ONSF) protects vision but does not cure headaches. CSF shunting (Lumboperitoneal or Ventriculoperitoneal shunt) treats both vision and headaches. Venous sinus stenting if severe transverse sinus stenosis with a significant pressure gradient is confirmed.
Patient Counseling & Advice
Emphasize that while headaches are severely debilitating, the primary goal of treatment is to save their vision. Regular ophthalmologic follow-up is non-negotiable, as vision loss can be silent and peripheral initially.
Follow-Up & Monitoring Schedule
Ophthalmology follow-up every 2-4 weeks initially for formal automated visual field testing (Humphrey) and OCT (Optical Coherence Tomography) of the optic nerve head, then spaced out as papilledema resolves.
Preventive Strategies
Weight maintenance and avoiding known offending medications (e.g., tetracyclines, large doses of Vitamin A).
Generally good if diagnosed and treated early. Most patients improve with weight loss and Acetazolamide. However, relapse occurs in 10-20%, usually corresponding with weight regain.